This year’s most-read articles on CKD highlighted research and insights on drug approvals, guidelines, and value-based care.
Phase 1 data presented by Andrew Brenner, MD, PhD, showed RNL-186 improved survival, reduced symptoms, and demonstrated ...
The ustekinumab (Stelara; Janssen Biotech) biosimilar DMB-3115 (Imuldosa; Accord BioPharma) demonstrated clinical efficacy and safety comparable to the reference product through 52 weeks in a recent ...
The 5 most-read breast cancer articles on AJMC.com this year included FDA approvals, emerging therapies for metastatic breast ...
LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92 ...
Chronic kidney disease (CKD) significantly amplifies cardiovascular (CV) risk, with CV disease remaining the leading cause of ...
Chronic kidney disease (CKD) is a well-established risk factor for cardiovascular (CV) disease because declining kidney ...
FLAMeS, a new convolutional neural network, enhances MS lesion segmentation accuracy using only T2-weighted FLAIR images, ...
The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted ...
Tom Kim, MD, of Sound Long-Term Care Management, discusses how serious illness and care coordination set these ACO patients ...
Lerodalcibep-liga, a once-monthly PCSK9 inhibitor, significantly reduces LDL-C in hypercholesterolemia, including HeFH, with ...
Menin inhibitors target the interaction between menin and the KMT2A complex, offering a breakthrough in treating acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback